Searching Content from Netherlands indexed under Life Sciences, Biotechnology & Nanotechnology ordered by Published Date Descending.
Links to Result pages
Amsterdam: The New Pharma Hub In Europe
As of March 2019, Amsterdam will be the proud home of the European Medicines Agency (EMA). It's been confirmed that the EMA will relocate its headquarters from London to Amsterdam due to Brexit.
16 Nov 2018
European Patent Office Amends Rules For Plant And Animal Patents
The patentability of plant and animal varieties has been a recurring topic of discussion over the years.
European Union
15 Aug 2017
ECJ: Non-Fertilised Human Ovum Activated By Parthenogenesis Could Be Patentable
The European Court of Justice recently ruled in International Stem Cell Corporation that parthenogenetically activated non-fertilised human ova are not human embryos.
26 Jan 2015
Nagoya Protocol Soon To Restrict Use Of Genetic Resources From Other Countries
The ‘Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization’ will enter into force on 12 October 2014.
17 Sep 2014
Advocate General: The Use Of Unfertilised Human Ova Is Patentable
The Advocate General of the European Court of Justice recently opined that parthenogenetically activated unfertilised human ova are not human embryos.
17 Sep 2014
ECJ Opens Door To SPCs For Safeners In Plant Protection Products
The European Court of Justice has decided that a safener can fall within the definition of an ‘active substance’ as outlined in Articles 1.8 and 3 of the Plant SPC Regulation.
European Union
17 Jul 2014
Recent European Developments Regarding Supplementary Protection Certificates (SPCs)
The Court of Justice of the European Union again handed down some important decisions in an attempt to clarify the interpretation of Regulation 469/2009.
European Union
7 Apr 2014
Court Of Appeal Of The Hague: One SPC Per Patent
On 27 August 2013, the Court of Appeal of The Hague rendered a remarkable judgment in preliminary injunction proceedings between Teva and Sanofi.
8 Oct 2013
US Supreme Court Ruling On Patent Eligibility Of DNA
The opinion of the US Supreme Court issued on June 13th, 2013 relating to Myriad Genetics' patent of BRCA genes is breaking news and is suggested to have a major impact on gene patenting.
1 Jul 2013
AstraZeneca - CJEU's Decision Re. Abuse Of Dominant Position (Losec)
In a judgment of 6 December 2012, the Court of Justice dismissed AstraZeneca's appeal against the General Court's decision that the company had abused its dominant position with respect to its blockbuster anti-ulcer drug, Losec.
21 Dec 2012
Healthcare Policy Meets Patent Law: Preferential Treatment Of Generics While The Originator Has Patent Protection
The Court of Appeals of The Hague has recently ruled that healthcare insurance companies, by inviting parties to bid in a tender to become the preferred supplier of a medicinal product which is still under patent protection, do not infringe the originator's patent and do not commit an "unlawful act".
27 Sep 2012
Generic Drug May Not Be Included In G-Standard Before Expiration Of Patent
The Dutch Supreme Court has ruled in legal proceedings between Glaxo and Pharmachemie, in which the question was whether a generic drug may already be included in the so-called G-Standard before the expiry of the patent of the original drug.
5 Sep 2012
The Importance Of An Explicit Secrecy Clause In Clinical Trials
European Patent Office, Board of Appeal, 7 July 2007, T 0007/07 (Ethinylestradiol and drospirenone for use as a contraceptive/BAYER PHARMA AG)
29 Aug 2012
AkzoNobel Signs Agreement To Sell Its Shares In ICI Pakistan
De Brauw Blackstone Westbroek has advised AkzoNobel on reaching an agreement to sell its 75.81 percent shareholding in ICI Pakistan Limited to the Yunus Brothers Group for €124.4 million (subject to a net debt and interest adjustment).
11 Aug 2012
Nautadutilh And Niaba Publish Report On Market Developments In The Dutch Biotechnology Industry
NautaDutilh and the Netherlands Biotech Industry Association (Niaba) are pleased to inform you that we have published our report on market expectations in the Dutch biotechnology industry.
22 May 2012
Novelty Destroying Acts In Clinical Trials
A recently published decision of the European Patent Office’s (EPO) Board of Appeal about European patents and clinical trials provides for interesting reading and for some important pointers about how to deal with clinical trials for medicinal products but also for medical devices as to not destroy novelty of a patentable invention with invalidity as result.
European Union
4 Jan 2012
More On Mobile Medical Apps, And On Clinical Decision Support Systems
I have been running around a lot lately doing presentations on conferences about medical devices and software, so I though it would be useful to give you a round-up on that subject.
22 Nov 2011
Stem Cell Patents In The EU: To Be Or Not To Be?
The patent of Oliver Brüstle that is at stake relates to purified neural precursor cells and to processes for their production from embryonic stem cells.
20 Oct 2011
Some Important Practical Points For ISO 14155 Compliant Clinical Trial Agreements In The EU, Part 2
If the clinical trial is to produce results in the form of data that the manufacturer of the investigational device wants to use to complete its technical file with a view to CE marking the device, it is critical for the manufacturer to own or at least have unfettered use of the data produced.
European Union
12 Oct 2011
Links to Result pages